Allison Garda

Dr. Allison Garda

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
AGAllison Garda
Allison Garda
PNPatrick J. Navin
Patrick J. Navin
KMKenneth W. Merrell
Kenneth W. Merrell
JMJames A. Martenson
James A. Martenson
MWMichelle A. Neben Wittich
Michelle A. Neben Wittich
Christopher L. HallemeierChristopher L. Hallemeier
Christopher L. Hallemeier

5 October 2024 in Brachytherapy
Verified
Journal Article
Closed access
CDChristopher L. Deufel
Christopher L. Deufel
EBEric E. Brost
Eric E. Brost
JDJustine M. Dupere
Justine M. Dupere
IPIvy A. Petersen
Ivy A. Petersen
MHMichael G. Haddock
Michael G. Haddock
AGAllison Garda
Allison Garda

24 January 2022 in Advances in Radiation Oncology
Verified
Journal Article
Open access
AGAllison Garda
Allison Garda
AHAshley E. Hunzeker
Ashley E. Hunzeker
AMAnn K. Michel
Ann K. Michel
SFSayeh Fattahi
Sayeh Fattahi
SSSatomi Shiraishi
Satomi Shiraishi
KCKimberly S. Corbin
Kimberly S. Corbin
Synchronous bilateral breast cancer (SBBC) poses distinct challenges for radiation therapy planning. We report our proton therapy experience in treating patients with SBBC. We also provide a dosimetric comparison of intensity modulated proton therapy (IMPT) versus photon therapy. Patients with SBBC who received IMPT at our institution were retrospectively analyzed. The clinical target volume (CTV) included the breast or chest wall and comprehensive regional lymph nodes, including axilla, supraclavicular fossa, and the internal mammary chain. Intensity modulated proton therapy and volumetric modulated arc therapy (VMAT) plans were generated with the goal that 90% of the CTV would recieve at least 90% of the prescription dose (D90>=90%). Comparisons between modalities were made using the Wilcoxon signed rank test. Physician-reported acute toxic effects and photography were collected at baseline, end of treatment, and each follow-up visit. Between 2015 and 2018, 11 patients with SBBC were treated with IMPT. The prescription was 50 Gy in 25 fractions. The median CTV D90 was 99.9% for IMPT and 97.6% for VMAT (P = .001). The mean heart dose was 0.7 Gy versus 7.2 Gy (P = .001), the total lung mean dose was 7.8 Gy versus 17.3 Gy (P = .001), and the total lung volume recieving 20 Gy was 13.0% versus 27.4% (P = .001). The most common acute toxic effects were dermatitis (mostly grade 1-2 with 1 case of grade 3) and grade 1 to 2 fatigue. The most common toxic effects at the last-follow up (median, 32 months) were grade 1 skin hyperpigmentation, superficial fibrosis, and extremity lymphedema. No nondermatologic or nonfatigue adverse events of grade >1 were recorded. Bilateral breast and/or chest wall and comprehensive nodal IMPT is technically feasible and associated with low rates of severe acute toxic effects. Treatment with IMPT offered improved target coverage and normal-tissue sparing compared with photon therapy. Long-term follow-up is ongoing to assess efficacy and toxic effects.

6 June 2025 in Brachytherapy
Verified
Journal Article
Closed access
CDChristopher L. Deufel
Christopher L. Deufel
EBEric E. Brost
Eric E. Brost
RDRobert Dahl
Robert Dahl
JCJordan McCauley Cutsinger
Jordan McCauley Cutsinger
BSBradley J. Stish
Bradley J. Stish
MHMichael G. Haddock
Michael G. Haddock

31 March 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
LVLuigi Antonio De Vitis
Luigi Antonio De Vitis
AGAnna Giudici
Anna Giudici
VTVincenzo Tarantino
Vincenzo Tarantino
SOStuart A. Ostby
Stuart A. Ostby
KBKelly Bruce
Kelly Bruce
GGGretchen Glaser
Gretchen Glaser

1 April 2024 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
YSYasamin Sharifzadeh
Yasamin Sharifzadeh
WBWilliam G. Breen
William G. Breen
WHWilliam S. Harmsen
William S. Harmsen
AAAdam C. Amundson
Adam C. Amundson
AGAllison Garda
Allison Garda
KCKimberly S. Corbin
Kimberly S. Corbin
PURPOSE: The COVID-19 pandemic led to rapid expansion of telemedicine. The implications of telemedicine have not been rigorously studied in radiation oncology, a procedural specialty. This study aimed to evaluate the characteristics of in-person patients (IPPs) and virtual patients (VPs) who presented to a large cancer center before and during the pandemic and to understand variables affecting likelihood of receiving radiotherapy (yield) at our institution. METHODS: A total of 17,915 patients presenting for new consultation between 2019 and 2021 were included, stratified by prepandemic and pandemic periods starting March 24, 2020. Telemedicine visits included video and telephone calls. Area deprivation indices (ADIs) were also compared. RESULTS: The overall population was 56% male and 93% White with mean age of 63 years. During the pandemic, VPs accounted for 21% of visits, were on average younger than their in-person (IP) counterparts (63.3 years IP v 62.4 VP), and lived further away from clinic (215 miles IP v 402 VP). Among treated VPs, living closer to clinic was associated with higher yield (odds ratio [OR], 0.95; P < .001). This was also seen among IPPs who received treatment (OR, 0.96; P < .001); however, the average distance from clinic was significantly lower for IPPs than VPs (205 miles IP v 349 VP). Specialized radiotherapy (proton and brachytherapy) was used more in VPs. IPPs had higher ADI than VPs. Among VPs, those treated had higher ADI ( P < .001). CONCLUSION: Patient characteristics and yield were significantly different between IPPs and VPs. Telemedicine increased reach to patients further away from clinic, including from rural or health care–deprived areas, allowing access to specialized radiation oncology care. Telemedicine has the potential to increase the reach of other technical and procedural specialties.